After the July 2026 FDA decision, people with mild cognitive impairment can start Leqembi, a drug for early Alzheimer's, at home instead of by IV. What did not change is who qualifies and the need for brain MRI safety monitoring. Mild cognitive impairment means early, noticeable changes in memory or thinking that do not yet block daily life. For Leqembi, it refers to impairment tied to Alzheimer's disease with amyloid buildup confirmed by testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resource:
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
Table of Contents
- How home initiation works
- How IV infusions compare
- Who still qualifies
- What monitoring and next steps look like
How home initiation works
According to Eisai and Biogen, the approved home start is 500 mg once a week as two back-to-back 250 mg autoinjector shots, with each shot taking about 15 seconds and given by the patient or a care partner Eisai and Biogen announcement. Subcutaneous means the drug goes under the skin, not into a vein.
According to BioArctic and Eisai, these initiation autoinjectors became available in the United States on August 24, 2026 launch update. That availability lets eligible patients avoid infusion-center visits for the start of treatment. Clinic visits are still needed for scans and safety checks.
How IV infusions compare
Before this change, starting treatment meant IV lecanemab at 10 mg/kg every two weeks, while weekly under-the-skin dosing at 360 mg was approved in August 2025 only as maintenance after 18 months of IV, according to Drugs.com reporting on Eisai and Biogen approval summary. IV initiation ties each dose to an infusion appointment, travel, and vein access. Home initiation shifts the dose to a brief weekly routine.
After 18 months of IV or under-the-skin initiation, patients may stay on initiation dosing or move to 360 mg weekly maintenance, according to Eisai and Biogen. Patients may also switch between IV and under-the-skin routes. The choice is about setting and routine, not a broader group of eligible patients.
Who still qualifies
Eligibility did not expand with home dosing. Treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Amyloid-beta pathology, a sticky brain protein tied to Alzheimer's, must be confirmed.
Confirmation usually means amyloid PET scan or spinal-fluid testing interpreted by the care team. People without confirmed amyloid, with more advanced dementia, or with dementia from another cause do not meet the indication. The FDA label ties use to the trial population studied.
What monitoring and next steps look like
Safety monitoring did not get lighter at home. Lecanemab carries a boxed warning for ARIA, brain changes seen on MRI.
ARIA-E is swelling fluid, and ARIA-H is small bleeds or iron deposits from bleeds. Care includes a recent baseline brain MRI, periodic MRIs during treatment, and prompt attention to symptoms such as headache, confusion, vision change, dizziness, or weakness. Home dosing removes infusions, not scan visits, exams, or calls about new symptoms.
- Confirm amyloid status and MRI timing with the prescribing clinic
- Decide who will give the two weekly shots and where supplies will be stored
- Put MRI dates, symptom numbers, and ride plans on one shared calendar
- Bring a list of blood thinners, past brain bleeds, and recent falls to that visit
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Dementia With Multiple Etiologies in the 2026 NIA Report: Why the Findings May Not Change Care Yet for Spouses and Partners
- Subjective Cognitive Decline Data for Public Health Action in 2026: How Adults in Midlife Can Read the Headline Carefully





